# SSRI Antidepressant Fluoxetine Improving Immunotherapy Efficacy in Advanced Hepatobiliary Malignancy Patients With Depression and Anxiety

> **NCT07174947** · PHASE2 · RECRUITING · sponsor: **First Affiliated Hospital of Wenzhou Medical University** · enrollment: 240 (estimated)

## Conditions studied

- Hepatobiliary Malignancy
- Fluoxetine
- Anxiety Disorders
- Depression Disorders

## Interventions

- **DRUG:** Fluoxetine (drug)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07174947
- **Lead sponsor:** First Affiliated Hospital of Wenzhou Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-01
- **Primary completion:** 2027-10-01
- **Final completion:** 2027-12-01
- **Target enrollment:** 240 (ESTIMATED)
- **Last updated:** 2026-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07174947

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07174947, "SSRI Antidepressant Fluoxetine Improving Immunotherapy Efficacy in Advanced Hepatobiliary Malignancy Patients With Depression and Anxiety". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07174947. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*